2022-08-22
Interim report second quarter, January 1 – June 30, 2022, Kancera ab (publ.), org.nr. 556806-8851
This is a translation of the interim report published in swedish on Januaryt 19th
Read More
2022-07-29
Correction: Interim report first quarter 2022, 1 January – 31 March 2022 Kancera AB (publ.), org.nr. 556806-8851
Due to technical reasons this report was only published as a press release, but did not show up in the Finacial reports section on the Kancera web page. This is now corrected. First quarter in brief January – MarchFinancial...
Read More
2022-05-25
Kancera receives patent grant in US for the drug candidate KAND145
Kancera AB announces today that the US Patent Office (USPTO) has issued a patent that protects the chemical structure of Kancera's fractalkine blocker KAND145. This patent, US 11,339,183, is owned by Kancera and is valid through 2039.
Read More
2022-05-23
Kancera provides operational update in connection with the interim report for the first quarter of 2022
This is a translation of a press release published in Swedish by Kancera AB (publ) on May 20, 2022.
Read More
2022-05-20
Interim report first quarter 2022, 1 January – 31 March 2022 Kancera AB (publ.), org.nr. 556806-8851
First quarter in brief January – MarchFinancial summary for the first quarter and the period January – March 2022· Net sales amounted to SEK 0 million (SEK 0.0 million).· R&D costs amounted to SEK 10,6 million (8,2 million).· Operating...
Read More
2022-02-18
Interim report for fourth quarter 2021, 1 January – 31 December 2021 Kancera AB (publ.), org.nr. 556806-8851
The year in brief October – DecemberFinancial summary for the fourth quarter Net sales amounted to SEK 0 million (0,0 million). R&D costs amounted to SEK 12,9 million (11,2 million). Operating profit for the fourth quarter amounted to SEK...
Read More
2021-12-06
Kancera appoints Peter Selin as Executive Vice President Corporate Development
Kancera AB (publ) today announces that Peter Selin has been appointed as Executive Vice President Corporate Development, responsible for business development, strategic partnerships and licensings. He will be part of the management team and report directly to the CEO.
Read More
2021-11-22
Kancera’s drug candidate KAND145 effectively reduces tumor size in a preclinical model of ovarian cancer
This is a translation of press release in Swedish (2021-11-22). Kancera AB (Nasdaq First North Premier Growth Market: KAN) today presents preclinical results that show that KAND145 effectively reduces tumor size in a disease model of ovarian cancer. These...
Read More
2021-11-19
Kancera reports top-line data from the phase IIa study with KAND567 in COVID-19 patients
This is a translation of a press release in Swedish published 2021-11-18. Kancera AB (Nasdaq First North Premier Growth Market: KAN) presents results from the exploratory phase IIa study with KAND567 in patients with COVID-19. The randomized double-blinded study...
Read More
2021-11-19
Interim report for third quarter 2021,1 January – 30 September 2021 Kancera AB (publ.), org.nr. 556806-8851
The year in brief Juli – SeptemberFinancial summary of the third quarter Net sales amounted to SEK 0 million (0,05 million). R&D costs amounted to SEK 10,9 million (8,8 million). Operating profit for the third quarter amounted to SEK...
Read More